The personal and societal toll of major depression is almost unfathomable. This year we will lose more than 42,000 people to suicide in the United States, the only top 10 cause of death in this country that has increased year after year. Much of this tragic outcome can be attributed to untreated, poorly treated, treatment-resistant, and undiagnosed major depression. In this regard, it is worth remembering the familiar quote, attributed to Joseph Stalin, "A single death is a tragedy, a million deaths is a statistic." Perhaps the personal misery and tragedy of major depression are best exemplified by the award-winning novelist William Styron's personal account in Darkness Visible:
"What I had begun to discover is that, mysteriously and in ways that are totally remote from normal experience, the gray drizzle of horror induced by depression takes on the quality of physical pain. But it is not an immediately identifiable pain, like that of a broken limb. It may be more accurate to say that despair, owing to some evil trick played upon the sick brain by the inhabiting psyche, comes to resemble the diabolical discomfort of being imprisoned in a fiercely overheated room. And because no breeze stirs this caldron, because there is no escape from this smothering confinement, it is
entirely natural that the victim begins to think ceaselessly of oblivion." 1 I had the opportunity to get to know Styron well in his later years and can attest to the severity of his depressive symptoms-the absolute inability to experience pleasure of any kind and a feeling of hopelessness.
The consequences of untreated or unremitted depression are quite dire, including an increased risk not only for suicide, but also for alcohol and substance abuse, as well as for a variety of major medical disorders (cancer, heart disease, stroke, kidney disease, and others). Perhaps of equal Cerebrum, August 2015 3 importance is the well-replicated observation that the longer a patient remains depressed, the less likely he or she is to achieve remission. Taken together, the linking together of findings indicates that the personal, societal, and economic consequences of undiagnosed or not well managed major depression are devastating and represent a major public health problem in the U.S. and worldwide.
Indeed, the latest Global Burden of Disease study revealed major depression to represent a major cause of disability. 2 All of the aforementioned considerations serve as the major impetus for developing predictors of treatment response in depressed patients.
The Current State of Evidence-based Treatments
The U.S. ECT is generally considered the most effective of all depression treatments, although no head-tohead, randomized, controlled trial has compared it with other interventions. It generally requires inpatient hospitalization, at least initially, and general anesthesia with nine to twelve treatments over a three-to four-week period. Its cost and concerns about memory loss and the stigma associated with "shock treatment" has precluded its more widespread use. VNS and rTMS are both FDA-approved for treatment-resistant depression; the former requires an invasive surgical procedure. Researchers have conducted relatively few controlled studies of these devices compared with the vast number of pharmacotherapy and psychotherapy treatment trials.
A Personalized Approach
With a plethora of drugs and psychotherapy approaches available, let us consider the problem psychiatrists encounter on a daily basis. A patient in my own practice serves as an example. A 50-year-old academic physician suffers from a classic major depressive episode associated with severe I want to recommend the treatment most likely to be successful in producing a complete remission of his depressive syndrome and relieving him of his considerable misery. What are the known and best-validated predictors of response? Our group has previously reviewed the scientific findings in this area. [3] [4] [5] [6] The most reliable predictor is past response, but in this case the patient has never been treated for depression. A positive response in first-degree family relatives is also predictive of a beneficial response to antidepressants, but again, this is not applicable to this patient. Some evidence suggests that certain subtypes of depression respond best to certain treatmentsmonoamine oxidase inhibitors (the first type of antidepressants developed) are believed to be the most effective for patients with so-called atypical depression characterized by hypersomnia, overeating, extreme rejection sensitivity, and feeling better in the morning than later in the day.
Combinations of antidepressants and antipsychotics or ECT are best for patients with major depression with psychotic features. However, neither of these subtypes are relevant to the patient I Dunlop, and Craighead) were colleagues of mine for many years, and we continue to collaborate on various projects. However, I was not involved in the following study.
Mayberg's study sought to identify a biomarker that could predict which type of treatment would benefit a patient based on the individual's brain activity. Using regional brain glucose metabolism as measured by positron emission tomography (PET) as a proxy for neural activity, her group sought to determine whether baseline resting state activity predicted remission after twelve weeks of treatment with either the selective serotonin reuptake inhibitor escitalopram (10 to 20 mg per day)
or sixteen sessions of cognitive-behavioral therapy. The study sample initially comprised eighty-two men and women who were randomized between the two treatments. Of these, sixty-five patients completed the study and thirty-eight had clear outcomes and acceptable PET data. The thirty-eight patients who comprise the analyzable data set were distributed as follows: eleven who went into remission with escitalopram (six non-responders) and twelve who did so with CBT (nine nonresponders). The major finding were that hypometabolism of glucose in the insula, likely reflecting reduced activity of neurons in this brain region, was associated with remission using CBT, and with poor response to escitalopram. Contrariwise, insula hypermetabolism, reflecting increased activity of neurons in this brain region, was associated with remission using escitalopram and with poor response to CBT.
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The authors conclude that baseline insula metabolism is the first objective marker to guide initial treatment selection in depression. Closer scrutiny of their data is worthwhile. First they eliminated from their primary analysis the responders to CBT or to escitalopram who did not go into remission.
More specifically, partial responders to escitalopram or CBT were excluded from the analysis. They did so in order to accentuate the differences between the extremes in the depressed population;
the results revealed clear differences in glucose metabolism in six regions: the right anterior insula, right motor cortex, left premotor cortex, right inferior temporal cortex, left amygdala, and precuneus.
When all six regions were compared, the right insula exhibited the greatest effect as a discriminator of treatment response, followed by the precuneus. When the whole sample was studied, right
Potential Treatment-Specific Biomarker Candidates. Mean regional activity values for remitters and nonresponders segregated by treatment arm are plotted for the six regions showing a significant treatment × outcome analysis of variance interaction effect. Regional metabolic activity values are displayed as region/whole-brain metabolism converted to z scores. Regions match those shown in Table 2 . Escitalopram was given as escitalopram oxalate. CBT indicates cognitive-behavioral therapy.
insular activity was positively correlated with the depression symptom severity scale, and with the Hamilton Depression Rating Scale (HRSD) score in the CBT treatment group while right insular activity was negatively correlated with the HRSD in the escitalopram treatment group.
This finding is quite provocative. If additional research can replicates these results, it suggests that a simple brain imaging test could reliably predict whether a given patient should be treated with psychotherapy or antidepressant medication. It also raises a plethora of additional questions:
 A wealth of data, now summarized in a research meta-analysis, indicate that MDD patients with a history of child abuse and neglect exhibit a poorer response to pharmacotherapy and psychotherapy and exhibit unique brain imaging differences. Such possibilities should not detract from the groundbreaking findings. This research group has always been willing to take great leaps forward, and they should be applauded for it. Subsequent studies will reveal if the insula is truly "the region" that predicts response to CBT versus a selective serotonin reuptake inhibitor such as escitalopram or whether other regions or biomarkers also need to be a component of the ultimate formula. This is part of the ongoing and exciting scientific process that is emblematic of the marriage of neuroscience and psychiatry. Ultimately, I believe this work will be judged as crucial in eventually attaining the goal all of us seek: a valid predictor of individual treatment response in depression, still the Holy Grail in psychiatry research. 
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